Copyright
©The Author(s) 2020.
World J Gastrointest Surg. Aug 27, 2020; 12(8): 355-368
Published online Aug 27, 2020. doi: 10.4240/wjgs.v12.i8.355
Published online Aug 27, 2020. doi: 10.4240/wjgs.v12.i8.355
Table 3 Comparison of liver function in Group A and Group C at the 1st week after treatment
| Group A | Group C | t/χ2 value | P value | |
| ALB (g/L) | 32.82 ± 5.93 | 31.32 ± 5.28 | 1.195 | 0.236 |
| ALT (U/L) | 48.29 ± 15.39 | 67.29 ± 22.93 | 4.351 | 0.000 |
| AST (U/L) | 51.73 ± 14.92 | 79.28 ± 20.28 | 6.921 | 0.000 |
| TBiL (μmol/L) | 23.93 ± 8.38 | 31.39 ± 9.29 | 3.771 | 0.000 |
- Citation: Zhang Y, Zhang MW, Fan XX, Mao DF, Ding QH, Zhuang LH, Lv SY. Drug-eluting beads transarterial chemoembolization sequentially combined with radiofrequency ablation in the treatment of untreated and recurrent hepatocellular carcinoma. World J Gastrointest Surg 2020; 12(8): 355-368
- URL: https://www.wjgnet.com/1948-9366/full/v12/i8/355.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v12.i8.355